#1INVENTING NEW MEDICINES WITH TARGETED PROTEIN DEGRADATION KYMERA November 2023#2Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business plans and objectives for our programs; plans and timelines for the preclinical and clinical development of our product candidates, including the therapeutic potential, clinical benefits and safety profiles of such product candidates; expectations regarding timing, success and data announcements of ongoing preclinical studies and clinical trials; our ability to initiate new clinical programs, including plans to submit investigational new drug (IND) applications; the initiation, timing, progress and results of our current and future preclinical studies and clinical trials of our current and prospective product candidates; our plans to develop and commercialize our current and any future product candidates and the implementation of our business model and strategic plans for our business, current and any future product candidates. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "assume," "believe," "could," "estimate," "expect," "goal," "intend," "may," "milestones," "objective," "plan," "predict," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events and actual results or events could differ materially from the plans, intentions and expectations disclosed herein. Any forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements including, without limitation, risks associated with: the timing and anticipated results of our current and future preclinical studies and clinical trials, supply chain, strategy and future operations; the delay of any current and future preclinical studies or clinical trials or the development of our drug candidates; the risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for KT- 474, KT-333, KT-413 and KT-253; our ability to successfully demonstrate the safety and efficacy of our drug candidates; the timing and outcome of any interactions with regulatory authorities; obtaining, maintaining and protecting our intellectual property; our relationships with existing and future collaboration partners; the impacts of current macroeconomic and geopolitical events. In addition, any forward-looking statements represent Kymera's views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera explicitly disclaims any obligation to update any forward-looking statements, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. As a result of these risks and others, including those set forth in our filings with the SEC, actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. Certain information contained in this presentation and statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources have evaluated the reasonableness or accuracy of the Company's internal estimates or research, and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 2#3KYMERA Recognized leader in Targeted Protein Degradation (TPD) Building a fully-integrated, global biotech company Focusing on I/I and Oncology, with disease-agnostic potential Accelerating forward integration through key strategic partnerships KYMERA ©2023 KYMERA THERAPEUTICS, INC. ● Overview Focused on unlocking high value, undrugged targets using TPD Advanced four programs to clinical stage to date, first degrader program in I/I with IRAK4 demonstrating degrader differentiation Demonstrated fidelity of translation of PK, PD and safety across four clinical programs in both immunology and oncology Demonstrated clinical activity in three programs in immunology and oncology Initiated two Phase 2 trials for KT-474/SAR444656, in potential blockbuster indications (HS & AD) with Sanofi Highly productive discovery engine delivering multiple INDs/year with expanding focus in I/I Well-capitalized with $435m of cash, enabling expansion of clinical impact into areas with large clinical and commercial opportunities PAGE 3#4KYMERA KYMERA ● ● Dosed first patient in KT-474 Hidradenitis Suppurativa Phase 2 clinical trial Initial patient dose generated first development milestone ($40M) from Sanofi Demonstrated initial KT-333 anti-tumor activity in Phase 1 clinical trial; additional disclosure expected in poster at ASH 2023 ● Recent Accomplishments Demonstrated proof-of-mechanism in KT-253 and initial antitumor activity in first patient cohort without typical MDM2 hematologic toxicity Reprioritized pipeline, allocating resources and capital to emerging immunology pipeline Extended cash runway into first half of 2026 ©2023 KYMERA THERAPEUTICS, INC. PAGE 4#5TARGET SELECTION Kymera: A Differentiated Approach to TPD Undrugged (UD) or inadequately drugged (ID) targets UD Transcription Factors (e.g. STAT3) KYMERA ID Degrader Advantage Over SMI (e.g. IRAK4, MDM2) Strong genetic validation within clinically validated pathway ©2023 KYMERA THERAPEUTICS, INC. PLATFORM Significantly differentiated investments Tissue- selective E3 Ligases New Molecular Glue Approach Enabling a whole new generation of clinical programs ● Novel strategy to address undrugged/ unligandable targets CLINICAL TRANSLATION Fidelity of translation of PK, PD and safety in 3 programs in immunology and oncology 0 Percent Change from Baseline IRAK4 -20 -40 -60 -80 -100- % Change from C1D1 Predose (Mean ± SEM) -20 0 4 8 12 16 20 24 28 32 36 40 -40 -60 -80- -100++ KT-333 Cycle 1 weeks 1 & 2 T T T T MAD PART C 1 2 3 4 5 6 T 7 8 9 10 11 12 Days in Study PAGE 5#6Clinical and Near-Term Clinical Pipeline of Novel Protein Degraders Immunology Programs IRAK4* Transcription Factor IL4/13 Pathway Scaffolding Kinase STAT3 Oncology Programs STAT3 MDM2 Potential Indication(s) HS, AD, RA, Other AD, Asthma, COPD, EoE, PN Psoriasis, IBD, Lupus, Other Autoimmune & Fibrotic Diseases Potential Indication(s) PTCL, LGL-L, CTCL, Solid Tumors Liquid & Solid Tumors Preclinical Phase 1 KYMERA ©2023 KYMERA THERAPEUTICS, INC. KT-474 - Hidradenitis Suppurativa KT-474 - Atopic Dermatitis 00 Preclinical KT-333 KT-253 Phase 2 Phase 1 Phase 2 *KT-474 partnered with Sanofi, with Kymera option to participate equally in the development and commercialization in the United States. Phase 3 Phase 3 Upcoming Milestones Topline HS Data 1H 2025 Topline AD Data 1H 2025 R&D Day January 2024 R&D Day January 2024 R&D Day January 2024 Upcoming Milestones Clinical Activity: ASH 2023 Clinical Activity: 2024 Rights with sanofi KYMERA KYMERA KYMERA Rights KYMERA KYMERA PAGE 6#7KYMERA IRAK4#8Degrading IRAK4: Best Approach to Block IL-1R/TLR driven Inflammation IRAK3 TLRs (TLR 2,4,5,7,8,9) signaling NFkB IL-1R/TLR Pathway IL-1 a/B, IL-18, IL-33, IL-36 $ Myddosome IKKS MyD88 IRAK4 IRAK1 IRAK2 TRAF6 IL-1R KYMERA ©2023 KYMERA THERAPEUTICS, INC. JNK/p38 c-Jun MINITAT secreted TNF-a, IFN-Y, IL-1B, IL-6, IL-8, IL-10, IL-12, IL-17, IL-23 Degrader Advantage Inhibitor Scaffolding Role JNK/p38 NFkB IRAK4 Degrader Kinase Role IRF5/7 Clinical Pathway Validation IL-1a/IL-13: Rheumatoid Arthritis, CAPS, Hidradenitis Suppurativa IL-1α: Atopic Dermatitis IL-1ß: Gout; CANTOS Outcomes Data in Atherosclerosis and Lung Cancer IL-18: Macrophage Activation Syndrome IL-36: Generalized Pustular Psoriasis, Atopic Dermatitis IRAK4 SMI: Rheumatoid Arthritis Human Genetics Adult humans with IRAK4 Null Mutation are healthy IRAK4 degrader has potential to achieve a broad, well-tolerated anti-inflammatory effect, providing multiple development opportunities in autoimmune inflammatory diseases PAGE 8#9● ● ● ● ● ● IRAK4 Degrader Best-in-Class Potential in Immune-inflammation Potential for Broad Activity Across Th1-Th17 and Th2 Diseases KT-474 IL-1R/TLR Lupus IBD Gout Psoriasis IRAK4 OC Th1-Th17/Neutrophils Hidradenitis Suppurativa Rheumatoid Arthritis ● ● ● ● Th2/Eosinophils Atopic Dermatitis Asthma COPD CRSWNP Combined global drug sales ~$120B Source: 1. GlobalData; 2. Evaluate Pharma;.3. Ahn. JAMA Otolaryngol Head Neck Surg. 2016; 4. Dash. Allied Market Research 2021 KYMERA ©2023 KYMERA THERAPEUTICS, INC. Indication AD HS RA SLE IBD Gout Psoriasis Asthma COPD CRSWNP ● 2022 Prevalence¹ (US/EU5/JP) 98 M 785 K 6.4 M 550 K 3.1 M 20.3 M 15.8 M 86.8 M 61.9 M 20.4 M³ 2022 Global Sales² $8.6 B $1.0 B¹ $27.9 B $1.8 B $23.6 B $1.1 M $24.6 B $17.7 B $9.6 B $2.6 B4 Limitations of Current Therapies Anti-Cytokine/Cytokine Receptor Antibodies o Target only 1-2 cytokines o Require injection Small Molecule Inhibitors o Limited pathway blockade (IRAK4 SMI) o Safety issues (JAK family) PAGE 9#10● ● ● ● KT-474 Phase 1 Data Supports Phase 2 Advancement Healthy Volunteers (HV), SAD and MAD Evaluated safety, tolerability and pharmacokinetics in 132 healthy volunteers SAD: oral doses of 25-1600 mg MAD: escalating doses up to 200 mg were administered for 14 consecutive days Robust ( >95%) and sustained IRAK4 degradation with single and multiple daily doses Broad inhibition of ex vivo TLR-mediated cytokine induction Generally well-tolerated across all dose groups KYMERA ©2023 KYMERA THERAPEUTICS, INC. ● ● ● ● HS and AD Patient Cohort Open label study in 21 patients with HS and AD Dose: 75 mg QD with food (equivalent exposure to 100 mg fasted), administered for 28 consecutive days Safety, PK and PD comparable to healthy volunteers Robust IRAK4 degradation in blood and skin with associated systemic anti-inflammatory effect in HS and AD patients Promising clinical activity observed in HS and AD PAGE 10#11Mean (± SE) Percent IRAK4 Change from Baseline 50 -20 -40 -60 -80 -100 ● ● ● KT-474 Healthy Volunteer Study: Robust and Sustained IRAK4 Degradation Leading to Broad Cytokine Impact 1 2 3 4 KYMERA Mean % Reduction of IRAK4 (Daily oral doses for 14 days) 7 Dosing period 14 Day 17 21 Detected by mass spectrometry in circulating PBMC Steady state IRAK4 reduction achieved between Days 7 and 14 Recovery towards baseline by Day 28 (2 weeks after last dose) 50-200 mgs approached Lower Limit of Quantitation (LLOQ) ©2023 KYMERA THERAPEUTICS, INC. Placebo 25 mg QD 50 mg QD 100 mg QD 200 mg QD 28 Ex Vivo Inhibition of 9 Disease-Relevant Cytokines, Day 7-14 R848 (TLR7/8) Stimulation Placebo (n = 9) 50 mg QD (n = 9) Mean (+SE) Maximum % Change from Baseline at Day 7 - 14 100 mg QD. (n = 8-9*) Pbo 50 mg QD 200 100 -50 -100 IFNY >500% -62% IL18 IL6 15% -59% 35% -18% IL8 IL10 -5% -28% -23% 2% 100 mg -85% -68% -53% -32% -50% QD Mean values > 200% have been replaced by 200 for visualization purposes *n=8 for LPS, n=9 for R848 IL12 3% -58% -72% IL17 107% -24% -46% IRAK4 MAD TNFa -7% -21% -59% PAGE 11#12Percent Change from Baseline IRAK4 PK/PD Correlation in Blood (Plasma/Monocytes) (FLOW) 13 ng/mL threshold -20 -40 -60 -80 KT-474 Plasma PK and IRAK4 Degradation in HS and AD Patients Dosed for 28 Days are Comparable to HV High KT-474 Exposure in HS and AD Patients Skin -100 MAD PART C 0 4 8 12 16 20 24 28 32 36 40 KT-474 Ctrough/ng/mL KT-474 concentrations in plasma lead to same level of IRAK4 degradation in HV (n=48) and HS/AD (n=20) patients Concentrations above 3 ng/mL lead to same level of degradation (>80%) in HV and Patients IRAK4 Levels in Blood (PBMC) in Patients at Day 28 (MS) KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. Mean (± SE) Absolute IRAK4 Levels by MS [fmol/µg protein] 1.00 0.75 0.50 0.25 0.00 I Day 28 HS and AD Patients IRAK4 Levels at Day 28 (n=4) near LLOQ protein) Mean (+SE) IRAK4 Levels in Skin (fmol/µg N Mean 400 0.0 Mean (± SE) KT-474 Concentrations [ng/mL for Plasma, ng/g for Skin] 300 0 Reduced IRAK4 in Skin Lesions of AD and HS Patients 0.3 Plasma Day 28 Skin Day 28 MAD Healthy Subjects (Baseline) 46 0.12 ▬▬▬▬▬▬▬▬▬▬‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒ H AD Patients HS Patients AD Patients (Baseline) (Baseline) (Day 28) 7 0.22 + 11 0.24 6 IRAK4 Patients 0.1 HS Patients (Day 28) 9 0.11 PAGE 12#13Disease-Relevant Genes Downregulated in Skin Lesions in ≥ 50% of Evaluable* AD (N=7) and HS (N=10) Patients at Day 28 (RNAseq) Substantial downregulation of many disease relevant genes in both HS and AD patients Downregulation exceeded 90% for many genes Broad anti-inflammatory signature with downregulation of genes responsible for: IL1 family cytokines Th1 Th17 Th2 ✓ Innate immunity KYMERA AD HS CXCL1 ©2023 KYMERA THERAPEUTICS, INC. AD-3- AD-6- AD-7- AD-4- AD-5- AD-2- AD-1- IFNG HS-3- HS-8- HS-2- HS-5 HS-4- HS-12- HS-9- HS-1- HS-6- HS-7- -7.5 CSF3 HS-3- HS-8 HS-5 HS-1 HS-9 HS-2 HS-4- HS-6- HS-12- HS-7- 0 log2(fold change) -5.0 -2.5 0.0 log2(fold change) 2 2.5 0.0 IL2RB AD-6- AD-3- AD-2- AD-7- AD-1- AD-4- AD-5- GZMB HS-5- HS-2- HS-3- HS-8 HS-12- HS-6- HS-7- HS-4- HS-9- HS-1 -3 -7.5 IL1B HS-8- HS-1- HS-3- HS-4 HS-5- HS-7 HS-9- HS-12- HS-6- HS-2- log2(fold change) -7.5 -5.0 -2.5 log2(fold change) flog2(fold change): -1 = 50% decrease, -2 = 75% decrease, -3 = 87.5% decrease -5.0 -2.5 log2(fold change) 0 log2(fold change) 0.0 6 2.5 IL5 AD-4- AD-5- AD-1- AD-3- AD-7- AD-2- AD-6- IL8 HS-5- HS-4- HS-8 HS-1 HS-3- HS-12- HS-7- HS-9 HS-6 HS-2 HS-12 HS-5- HS-3- HS-4 HS-1 HS-8 HS-7 HS-9 HS-6- HS-2- -5.0 IL36A -7.5 0 log2(fold change) -2.5 0.0 log2(fold change) 1 2.5 5.0 0.0 NLRP3 AD-3- AD-5- AD-2- AD-4- AD-7- AD-1- AD-6- IL2RA HS-4- HS-5- HS-3- HS-8- HS-2- HS-1- HS-9- HS-12- HS-6- HS-7 -2 -4 IL17A HS-5- HS-8- HS-3- HS-4 HS-1- HS-7 HS-2 HS-12- HS-9- HS-6- 2 log2(fold change) 0 -2 log2(fold change) -5.0 -2.5 log2(fold change) log2(fold change) *Evaluable patients for whom the samples were of sufficient quality for analysis. 0 IRAK4 Patients PAGE 13#14Mean % Change (+/- S.E. of mean) 0 -10 -20 -30 -40 -50 -60 0 KT-474 HS: Significant Reductions in AN Counts Leading to HISCR Responses and Significant Reductions in Pain and Pruritis 7 Mean % Change in Total AN Counts Over Time -27.4 -19.9 14 All HS Patients (N=12)* Moderate to Severe (N=10) -49.6 21 Day -31.6 28 -45.4 -40.6 35 -46.1 -50.7 42 KYMERA ©2023 KYMERA THERAPEUTICS, INC. 80 70 % of HISCR Responders (80% CI) 8 8 50 30 20 10 0 0 7 HISCR50 Responders 30 14 25 21 Day 30 28 25 50 42 35 50 42 42 *One patient is censored for Day 35 and Day 42 since the patient started on ustekinumab, steroids and abx on Day 34. Mean % Change (+/- S.E. of Mean) Mean % Change (+/- S.E. of Mean) Mean % Change in Average Pain Over Past Week -10 -20 -30 -40 -50 -60 -70 -80 0 -10 -20 -50 -60 -70 -80 -30 -29.1 -40 -90 0 -100 -26.9 0 7 -23.4 7 -38.7 -17 14 -41.7 -40.1 -56.1 21 Day Mean % Change in Worst Pruritus Over Past Week -26.1 F-41.9 14 -48.6 -64.6 -24 28 -67.8 21 Day -53.8 -65.7 -48.6 28 35 -60.1 -59.7 -62.3 -60.4 42 -53.6 35 -61.6 IRAK4 Patients -68.4 42 PAGE 14#15● ● ● ● KT-474 Showed Meaningful Signs of Clinical Activity in HS, Comparing Favorably to Placebo Benchmarks and SOC AN Count reductions most profound in moderate and severe patients Highly competitive HISCR response rates continued to improve after cessation of dosing Pain and pruritus response rates and reductions significantly higher than placebo and SOC benchmarks Physician Global Assessment (PGA) scores improved in 5 of 12 patients, including 1 moderate disease patient with full disease clearance, and stable in the others ΔΑΝ Count AN Count 0/1/2 HISCR50 HISCR75 Pain NRS30 Responder KT-474 Part C (All/Moderate to Severe) Day 28 Day 42 -32% / -50% 42% / 50% 25% / 30% 8% / 10% 50% / 60% -46% / -51% 33% / 40% 42% / 50% 25% / 30% 50% / 60% Placebo Benchmarks Week 4 -15%¹ 24 to 26%3 19 to 30% 3,4 5%4 18 to 23% 3,5 Adalimumab Phase 2 and 3 Week 4 -31%¹ 28 to 47%2,3 29 to 51% 3,4 20%4 IRAK4 Patients 39 to 58%2,3,5 The Adalimumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only. ¹Kimball AB, et al. Ann Intern Med 2012;157:846-55; 2Morita A, et al. J Dermatol 2021;48:3-13; ³Kimball AB, et al. NEJM 2016;375:422-434;4Glatt S et al. JAMA Dermatol 2021;157:1279-88; 5Scheinfeld, et al. Derm Online J 2016:22 KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 15#16Mean % Change in EASI Score (+/-S.E. of Mean) -10 20 -30 40 -50 -60 O KT-474 AD: Significant Reduction in EASI Score and Pruritus 0 Mean % Change in EASI Score Over Time (N=7) 7 14 -17.9 21 Day -37.1 28 35 -27.6 -36.4 KYMERA ©2023 KYMERA THERAPEUTICS, INC. 42 Mean % Change (+/-S.E. of Mean) 10 -10 -20 -40 -50 -70 -80 0 Mean % Change of Worst Pruritus Over Time (N=7) -5.8 1 7 -6.6 -32.1 14 -33.3 -43 - 44 -35.6 -44.6 -51.2 21 Day 28 Past Week Past 24 Hours -38.9 -44.6 35 -51.9 -62.9 42 % of Pruritis Responders (80% CI) 100 90 70 50 30 20 10 O Patients with ≥4 Unit Reduction from Baseline in Worst Pruritus (N=7) 0 7 29 14 43 29 21 Day Past Week Past 24 Hours 71 57 28 57 43 35 IRAK4 Patients 71 57 42 PAGE 16#17● ● ● KT-474 Showed Meaningful Signs of Clinical Activity in AD, Comparing Favorably to Placebo Benchmarks and SOC Encouraging initial EASI score reductions sustained after cessation of dosing Peak pruritus reductions, and responder rates, significantly greater than placebo and SOC benchmarks Investigator Global Assessment (IGA) scores improved in 2 of 7 patients and remained stable in the others AEASI APeak Pruritus NRS Peak Pruritus NRS Responder (week/24hrs) KT-474 Part C Day 28 -37% -52% 57%/71% Day 42 -36% -63% 57%/71% Placebo Benchmarks Week 4 -12 to -25%* -11%1 4 to 17%** Dupilumab Phase 3 Week 4 -52%¹ -34%¹ IRAK4 Patients 23 to 40% 1,2 *Range from 7 different Phase 2 and Phase 3 trials; **Range from 10 different Phase 2 and Phase 3 trials; ¹Simpson EL, et al. NEJM 2016;375:2335-2348; 2Bieber T, et al. NEJM 2021;384:1101-1112; The Dupilumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 17#18● ● ● Adverse Events Related to KT-474 (Occurring in >1 Patient) Adverse Event (Preferred Term) KYMERA Headache Fatigue Diarrhea # of Patients 6 ©2023 KYMERA THERAPEUTICS, INC. 4 2 Severity (# of Pts) Mild (5) Severe (1) Mild (4) Mild (2) Outcome (# of Pts) Recovered (6) Recovered (4) No SAEs, no drug-related infections, and no AEs observed leading to dose interruption or discontinuation No QTc-related AEs observed Recovered (2) QTc declines to baseline with continued dosing and sustained plasma exposure through Day 28 Profile is maintained through day 42 upon cessation of dosing after Day 28 IRAK4 Patients PAGE 18#19● Phase 1 results in healthy volunteers and patients support Phase 2 advancement Sanofi responsible for program development costs Kymera retains option (before Phase 3) for cost and profit sharing First development milestone achieved in Q4 2023 $40 million for first patient dosed in HS trial Additional milestone payable upon first patient dosed in AD trial Topline data from two ongoing trials expected 1H 2025 Kymera and Sanofi evaluating opportunities to expand indications beyond HS and AD ● KT-474: Oral Agent with Potential to Achieve Broad, Well-Tolerated Anti-Inflammatory Effect in Multiple Diseases ● KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 19#20KT-474/SAR444656: Hidradenitis Suppurativa (ZEN) Design: Double blind, placebo-controlled, 2-arm randomized trial; KT-474 oral tablet or placebo once-daily Enrollment: up to 99 subjects Duration: 16 weeks on therapy + 4 weeks of follow up Primary Outcome Measure: Percent change from baseline in total abscess and inflammatory nodule (AN) count Select Secondary Outcome Measures: ● ● ● ● ● Proportion of patients achieving HiSCR50, AN Count ≤2 Absolute change from baseline in IHS4 Ongoing Phase 2 Trials in HS and AD Atopic Dermatitis (ADVANTA) Design: Double blind, placebo-controlled, 3-arm randomized trial; KT-474 dose 1 oral tablet, KT-474 dose 2 oral tablet or placebo once-daily Enrollment: up to 115 subjects Duration: 16 weeks on therapy + 4 weeks of follow up Primary Outcome Measure: Percent change from baseline in EASI Proportion of patients with improvement in Hurley Stage, AN50 Change from baseline in reported daily worst pain HS-Skin Pain-NRS Proportion of participants achieving at least 30% reduction and at least 1 unit reduction in daily worst pain using HS-Skin Pain-NRS Primary Completion (Estimated): February 2025 Select Secondary Outcome Measures: Proportion of participants with vIGA-AD of 0 or 1 and a reduction from baseline of 22 points ● ● Proportion of participants achieving EASI-50 EASI-75 EASI-90 Proportion of participants with reduction of weekly average of daily PP-NRS by 24 points from baseline Percent change from baseline in weekly average of daily PP-NRS Absolute change from baseline in weekly average of daily PP-NRS Primary Completion (Estimated): January 2025 ● Additional information on the Phase 2 studies can be found at www.clinical trials.gov; identifier NCT06028230 (HS) and NCT06058156 (AD); Study Sponsor: Sanofi sanofi KYMERA HISCR50: Hidradenitis Suppurativa Clinical Response 50 | IHS4: International Hidradenitis Suppurativa Severity Score System | HS-Skin Pain-NRS: HS-Skin Pain-Numerical Rating Scale EASI: The Eczema Area and Severity Index; vIGA-AD: validated Investigational Global Assessment; PP-NRS: Peak Pruritus Numeric Rating Scale KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 20#21KYMERA STAT3#22● ● • KT-333 is a potent highly selective heterobifunctional small molecule degrader of STAT3 ● ● KT-333: STAT3 Degrader in Oncology High degree of validation of JAK-STAT pathway in oncology and immuno-oncology supported by >25k publications Traditionally undrugged target First-in-class opportunity to address STAT3 driven pathology across large and diverse indications Opportunities in STAT3-dep. malignancies (e.g., T cell maligs., DLBCL, AML) and drug resistant tumors (e.g., TKI res. oncogene-driven solids) KYMERA STAT3 Has Unique Tumor Cell Intrinsic and Extrinsic Mechanisms Intrinsic: Hyperactivation of STAT3 via either receptor signaling, or hotspot mutations promotes gene expression programs involved with survival, proliferation, stemness and metastasis of tumor cells ● ©2023 KYMERA THERAPEUTICS, INC. ● Prevalence Incidence ~75k ~4-8k ~30k ~3k ~4.5k <1k Solid Tumors, PD-1 Combo (e.g. Stage IV MSI-H CRC) ~30k ~5k Source: Bionest, NCI, SEER. GlobalData, LLS; ROW includes EU, UK, Japan and China. Peripheral T-cell lymphoma (PTCL) Cutaneous T-cell lymphoma (CTCL) Potential Clinical Activity Based on Preclinical Data: Single agent activity in heme (i.e. CTCL, PTCL, LGL-L); potential activity in solid tumors in combination Large granular lymphocyte leukemia (LGL-L) Extrinsic: STAT3 promotes the differentiation and activity of immunosuppressive and endothelial cells, resulting in an immunosuppressive tumor microenvironment Opportunities in multiple heme and solid tumor indications that are not responsive to immune checkpoint inhibitors Cytokine Growth Factor Receptor Receptor JAK JAK U.S. P P STAT3 SRC STAT3 STAT3 STAT3 STAT3 P R.O.W. Prevalence Incidence ~27k ~15k ~67k ~6k ~24k ~3k ~78k ~20k Adrenergic Receptor W RT PAGE 22#23KT-333 Highly Active on Intermittent Dosing Regimens Complete Tumor Regressions Associated with Robust STAT3 KD for ~48h in Preclinical Models KYMERA Tumor Volume (mm³) Mean, +SEM 3000 2000 1000 SU-DHL-1 Weekly Dosing Vehicle KT-333, 5 mg/kg, QW KT-333, 10 mg/kg, QW HH 10 HH 5 15 Days (Post-randomization) 20 ©2023 KYMERA THERAPEUTICS, INC. 25 Dose- and degradation-dependent tumor growth inhibition observed with once-weekly dosing in ALK+ ALCL 10 mg/kg sufficient to drive full tumor regression in SU-DHL- 1 that was durable for multiple weeks after the last dose (on day 14) 100000 KT-333 Concentration (ng/ml or ng/g) 10000 1000 100 10 0 Preclinical PK/PD •Tumor PK 48 Plasma PK 96 Time (hr) 144 Tumor PD 192 240 Based on preclinical model (STAT3 dependent ALK+ ALCL), target PD ~90% STAT3 KD for ~48 hours to achieve robust anti-tumor activity 150 100 50 % of Vehicle Control PAGE 23#24KT-333: Phase 1, Multicenter, Dose-Escalation and Expansion Trial to Evaluate KT-333 in Adult Patients with PTCL, CTCL, LGL-L, and Solid Tumors 0.05 Key Objectives Primary Secondary 0.10 Exploratory ● ● ● Phase 1a (n up to 40) R/R Lymphoma/Leukemia or Solid Tumors Regimen: mg/kg IV Infusion weekly ● 0.20 0.40 DLX Predicted clinically efficacious doses Phase 1a Safety/Tolerability and MTD and RP2D PK Parameters of KT-333 Preliminary Estimates of Activity PD Effects of KT-333 MTD: Maximum Tolerated Dose. RP2D: Recommended Phase 2 Dose. ORR: Overall Response Rate KYMERA ©2023 KYMERA THERAPEUTICS, INC. ● ● MTD/RP2D Expansion* ● Phase 1b Opportunities Cohort 1: PTCL Phase 1b • Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors Cohort 2: CTCL PD Effects of KT-333 Cohort 3: LGL-L Cohort 4: Solid Tumors Preliminary Clinical Activity (ORR, DOR, PFS, DCR, OS) PK Parameters of KT-333 PAGE 24#25Overall Safety Profile: As of May 1, 2023 (ICML) Tumor types enrolled: CTCL (n=2), PTCL (n=1), and solid tumors (n=10, including colorectal [2], appendiceal, anal, pancreatic, cholangiocarcinoma, peritoneal, endometrial, ovarian and head & neck) Preferred Term Number of Patients with Adverse Event Occurring in ≥2 Patients (n, (%)) Dose Level 1 0.05 mg/kg (n=4) Dose Level 2 0.1 mg/kg (n=4) All Related Dose Level 3 0.2 mg/kg (n=3) All Dose Level 4 0.4 mg/kg (n=2c) All All Related 2 (50) 2 (50) 1 (25) 1 (25) 1 (25) 1 (25) Fatigue 1 (25) Anemia 2 (50) Constipation 1 (25) Nausea 1 (25) Dehydration 1 (25) Dizziness 1 (25) Skin infection 1 (25) (a) All Grade 1 and 2 events except the following: 1 patient with Gr. 3 abdominal pain and 1 patient with Gr. 3 fatigue that were not related to KT-333. (b) No Grade 4 or Grade 5 events. 1 (33.3) 1 (33.3) Related 1 (33.3) KYMERA ©2023 KYMERA THERAPEUTICS, INC. Related Overalla, b (N=13) All 4 (30.8) 3 (23.1) 3 (23.1) 3 (23.1) 2 (15.4) 2 (15.4) 2 (15.4) Relatedd (c) At time of data cut off, DL4 had enrolled two patients and no AEs had been reported. (d) AEs related to KT-333 (n=1 each): Gr. 1: abdominal pain upper, LDH increase, and rash. Gr. 2: diarrhea; hypothyroidism; and squamous cell carcinoma (SCC) of the skin in CTCL patient with history of prior UVB treatment and recurrent skin SCCs considered possibly related. Summary: At the time of the data cut off (May 1, 2023), KT-333 was well tolerated, with no dose limiting toxicity observed and no serious adverse events considered related to KT-333 PAGE 25#26Plasma KT-333 Concentration (ng/mL) Mean (± SE) 1200 1000- 800 600 400- 200 0 0 KYMERA 2 Consistent Plasma PK Across the Evaluated Dose Levels: as of May 1, 2023 (ICML) 4 Week 1 Plasma PK HH 6 HH 8 Time (h) ©2023 KYMERA THERAPEUTICS, INC. DL1: 0.05 mg/kg DL2: 0.1 mg/kg DL3: 0.2 mg/kg 24 PK Parameter Cmax (ng/mL) AUC last (ng.h/mL) Vd (L/kg) CL (L/h/kg) t₁/2 (h) DL1: 0.05, mg/kg (n=4) Day1 307 (30.5%) 1550 (65.7%) 0.277 (17.1%) 0.0447 (62.7%) Week 1 PK Parameters 6.25 (78.8%) Day 8 280 (22.9%) 1450 (35.2%) 0.270 (22.2%) 0.0380 (35.2%) 5.26 (28.2%) DL2: 0.1 mg/kg (n=2) Day 1 382 (405, 359) 1820 (2120, 1520) 0.315 (0.293, 0.337) 0.0565 (0.047, 0.0659) 3.93 (4.32, 3.55) Day 8 497 (590, 403) 1620 (2090, 1140) 0.218 (0.200, 0.236) 0.0687 (0.048, 0.089) 2.36 (2.90, 1.82) Mean (%CV) shown for DL1; Mean (individual values) shown for DL2 and DL3. Subject 103-001 (DL2) excluded due to inconsistency in PK profile. DL3: 0.2 mg/kg (n=2) Day 1 1020 (1130, 902) 3150 (3050, 3250) 0.388 (0.374, 0.401) 0.0636 (0.0656, 0.0616) 4.23 (3.95, 4.51) Day 8 1070 (1200, 932) 4770 (4350, 5190) 0.243 (0.258, 0.229) 0.0422 (0.0459, 0.0385) 4.01 (3.89, 4.12) As of the data cut-off date of May 1, 2023. PAGE 26#27Up to 88% Mean Maximum Nearing Desired Degradation Profile at DL3 as of May 1, 2023 (ICML) -20 -40 DL2 wall DL3 Cycle 2 weeks 1 & 2 T T T 8 9 10 11 12 29 30 31 32 33 34 35 36 37 38 -60 -80 -100 KT-333 ● ● ● Time course of STAT3 degradation Method: Targeted Mass Spectrometry 1 Cycle 1 weeks 1 & 2 T T 2 T 3 4 5 6 7 Days in Study Maximum Degradation across individual patients Cycle 2 (D29-D37) DL1 KYMERA ©2023 KYMERA THERAPEUTICS, INC. -50 -60 -70 -80 -90 -100 DL1 Cycle 1 (D1-D12) DL2 ● 1 • 1 DL3 DL2 DL3 Values below LLOQ Dose-dependent STAT3 degradation Mean maximum degradation of up to 85.4% in Cycle 1 and 88.4% in Cycle 2 Weekly maximum reductions of up to 90-91% Profile at or nearing STAT3 degradation shown to lead to strong antitumor effects in preclinical models As of the data cut-off date of May 1, 2023. PAGE 27#28KT-333 Achieved STAT3 Pathway Inhibition and Downregulation of Inflammatory Biomarkers in Blood Maximum % Decrease in Plasma SAA (Mean ± SEM) Maximum % Decrease in Plasma CRP (Mean ± SEM) -20- -40- -60- -80- -100- -20- -40 -60- -80- -100 00 L O to SAA ● O O- C1 Week 1 C1 Week 2 CRP O OTC -0 to O O C1 Week 1 C1 Week 2 DL1 DL2 DL3 DL1 DL2 DL3 KYMERA ©2023 KYMERA THERAPEUTICS, INC. % Change from C1D1 Predose (Mean ± SEM) ● ● ● ● 300 200 100 -0 -50 -75 KT-333 SOCS3 T DL1 DL2 DL3 1 2 3 4 5 6 7 8 9 10 11 12 29 30 31 32 33 34 35 36 37 Days in Study SOCS3 % Change 100- -50- DL2 DL3 -75 -50 STAT3% Change -87.5 O Dose-dependent reduction in SOCS3 mRNA during Cycles 1 and 2 Correlation between changes in STAT3 protein and SOC3 mRNA Additional gene expression changes measured in peripheral blood presently being analyzed Reductions in plasma SAA and CRP, STAT3 regulated acute phase proteins As of the data cut-off date of May 1, 2023 PAGE 28#29As of abstract cutoff date: July 10, 2023 21 patients treated at 5 dose levels with mean 5.8 doses 8 liquid tumors, 13 solid tumors ● ● ● ● ● KT-333: ASH 2023 Abstract Summary ● ● SOCIETY AM OF 12 evaluable for disease response as of cutoff date 1 CTCL and 1 PTCL patient at DL2 evaluable with one partial response observed in CTCL patient after two cycles HEMA 10 solid tumors patients (DL1-4) evaluable, with stable disease observed in 3 patients after two cycles at DL3 and DL4 Robust dose-dependent target knockdown in DL1-4, with DL3 and beyond at levels associated with anti- tumor activity in preclinical models Most common AEs were Grade 1 and 2 constipation, fatigue, nausea and anemia No drug related SAES or DLTs observed; dose escalation ongoing Findings support clinical activity with weekly IV infusion Additional data, including other hematological tumor patients, to be presented during poster session at ASH Annual Meeting on December 10 KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 29#30As of May 1, 2023, data cutoff (ICML): PK and PD profiles in DL1-3 consistent with preclinical data ● ● ● KT-333: Desired Translation of PK, PD and Safety ● Proof-of-mechanism for KT-333 demonstrated with up to 88% mean max degradation of STAT3 in peripheral blood mononuclear cells DL-3 profile is nearing 90% target degradation that led to robust antitumor activity in STAT3-driven preclinical tumor models Most common AEs were Grade 1 and 2 and included fatigue and gastrointestinal symptoms; no DLTs observed or drug related SAEs Initial antitumor activity disclosed in ASH abstract Additional data expected at ASH: Dec. 10, 2023 KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-Class Opportunity to Address STAT3-Driven Pathology Across Diverse Indications First heterobifunctional degrader against an undrugged target in the clinic Clinical development strategy includes monotherapy direct registrational path in STAT3 dependent T cell malignancies Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors to be informed by preclinical data and planned analysis of TME remodeling in solid tumor biopsies from ongoing trial PAGE 30#31KYMERA MDM2#32KT-253: Potent MDM2 Degrader and Best-in-Class p53 Stabilizer • KT-253 is a novel, highly potent and selective heterobifunctional MDM2 degrader • MDM2 is the E3 ligase that modulates p53, the largest tumor suppressor • Cancer genetics: p53 is NOT mutated in almost 50% of tumors • MDM2 overexpression and amplification can inactivate p53 • Large opportunity in wide variety of cancers Benefits of MDM2 Degradation • KT-253, unlike small molecule inhibitors, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53 • Broad franchise opportunities available for this mechanism (over 50% of tumors are p53 WT); focused on indications with specific sensitivity to degrader mechanism, through a biomarker strategy Clinical Activity Based on Preclinical Data: Strong antitumor activity in a wide variety of heme and solid tumors with an emerging signature (undisclosed) KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. MDM2 CRISPR Sensitivity Score 0.6 Dependency of p53WT cells on MDM2 0.4 0.2 O -0.2 -0.4 -0.6 -0.8 -1 -1.2 -1.4 -1.6 -1.8 -2 -2.2 DNA Damage p53 p53MUT p53WT Hypoxia Stressors MDM2 Graph generated with data obtained from DepMap.org p53 Cell Line Oncogenes p53 ub ub MDM2 Tumor Suppression Other p53 Degradation p53 Targets Feedback Loop Cell Cycle Arrest (p21, Ptprv) Apoptosis (Noxa, Bax, Puma) PAGE 32#33KT-253 is a potent MDM2 degrader % MDM2 Remaining KT-253 is Superior to MDM2/p53 Small Molecule Inhibitors KT-253, unlike SMI's such as DS- 3032, strongly stabilizes p53... ... which leads to superior tumor cell killing (pM range) p53 MSD, 2h RS4;11, 24h CTG CO DMSO Company 300 250 200 150 100 80 60 40 20 0 KT-253 + DS-3032 Baseline 100000 0.0001 MDM2-HiBiT 0.001 0.01 Compound 0.1 Concentration, μM DC50=0.4nM Clinical stage RS4-11 IC50 (nM) (AML Cell Killing) MDM2-HiBiT, DC50 (nM) (Degradation) 10 3000 2500 2000 0.3 0.4 1500- 1000 500- 0.00001 KT-253 Kymera Phl 0- KT-253 DS-3032 0.0001 0.001 0.01 Concentration, μM DS-3032 Sankyo/Rain Ph II / combo AML 67 10 RG7388 Roche Ph II / III 220 100 80- 60 40- 20 -20 TO000'0 KT-253 DS-3032 620 SAR405838 Sanofi Paused 0.0001 0.001 0.01 0.1 Concentration, μM HDM201 Novartis PhI/II 163 DMSO 10 AMG-232 Amgen/Kartos Multiple Ph II 280 KT-253 is >200-fold more potent in tumor cell killing assays than SMIs due to its mechanism of action Proteomics show selective degradation of KT-253 KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 33#34KT-253 Potently Degrades MDM2 leading to Pathway Impact and Antitumor Activity Superior to SMI in ALL and AML Models Relative Quantification (% Vehicle, p53/ACTB) ● 2500 2000 1500- 1000 500 0 MDM2 Degradation Leads to Superior P53 Upregulation vs SMI KYMERA %MDM2 Remaining (Norm. to Vehicle, ACTB) 250 1 8 24 200 150 100 50 0 MDM2 Protein Levels 1h post dosing 6% p53 Protein Levels 8% 1 8 24 1 8 24 1 8 24 1 8 24 Time (Hours) Relative Quantification (% Vehicle, GDF15/IPO8) 10000 8000 6000 GDF15 Protein Levels p53 Activation 4000 2000 ©2023 KYMERA THERAPEUTICS, INC. Vehicle KT-253 3 mg/kg SD KT-253 1 mg/kg SD DS-3032 30 mg/kg QDx3 DS-3032 100 mg/kg QDx3 0 Targeted proteomic analysis of RS4;11 tumors demonstrates robust degradation of MDM2 one hour post dosing and associated pathway activation biomarkers including p53 and GDF15 I 1824 1 824 1 8 24 1 8 24 1 824 1 824 Time (Hours) MDM2 Degradation Leads to Superior Antitumor Responses in AML and ALL Preclinical Models Tumor Volume (mm³) Mean ± SEM Tumor volume (mm³) Mean ± SEM 2500 2000 1500 1000 500 0 2500 2000 1500 1000 500 0 O 14 7 Days Post Treatment 21 7 14 Days Post Treatment 21 28 28 RS4;11 Vehicle DS-3032 30 mg/kg PO, 3 on/11 off DS-3032 100 mg/kg PO, 3 on/11 off → KT-253 1 mg/kg IV, SD →KT-253 3 mg/kg IV, SD MV4;11 Sustained tumor regressions in RS4;11 (ALL) and MV4;11 (AML) CDX models after a single 3 mg/kg KT-253 dose No efficacy observed with clinically relevant dosing regimen of SM (DS- 3032) PAGE 34#35● DLX ● KT-253 Phase 1a: Study Design and Arm A Enrollment Status Dose Level 1 0.05 mg/kg (n=3) Dose Level 2 0.1 mg/kg (n=4) Dose Level 3 0.17 mg/kg (n=2) ● Solid Tumors/Lymphoma DLXH1 Pharmacologically Active Dose in ST/L DLxt2 Phase 1a DLY DLn DLy+1 R/R high-grade Myeloid Malignancies/ALL DLY +2 Clinical Trial Design Arm A: R/R Solid Tumors and Lymphomas 9 patients enrolled across first three dose levels Arm B: R/R high-grade Myeloid Malignancies/ALL Enrollment initiated MTD/RP2D DLn • Antitumor activity in dose level 1 • No DLTs or hematological toxicity Regimen: IV infusion once every 3 weeks Initial Results: Arm A (Data cut-off: October 20, 2023) • Robust PD in blood in first two dose cohorts (POM) KYMERA ©2023 KYMERA THERAPEUTICS, INC. MTD/RP2D Arm A Enrollment Age (years) Mean (range) Gender n, (%) Female Male # of Prior Therapies n, (%) 2-3 >3 Mean (range) Tumor type n, (%) Merkel Cell Carcinoma Fibromyxoid Sarcoma Uveal Melanoma Rectal Prostate Adenoid Cystic Renal Cell Osteosarcoma KT-253 Cycles Received Mean (range) 57.3 (42, 66) 2 (66.7) 1 (33.3) 1 (33.3) 1 (33.3) 4.3 (1,9) 1 (33.3) 1 (33.3) 1 (33.3) 4.7 (2-6) 64.3 (55, 74) 2 (50.0) 2 (50.0) O 4 (100) 6.8 (4, 9) 1 (25.0) 1 (25.0) 1 (25.0) 1 (25.0) 1.3 (1-2) 50 (43, 57) 1 (50.0) 1 (50.0) 2 (100) O 2.5 (2, 3) 1 (50.0) 1 (50.0) 1 (NA) Overall (N=9) 58.8 (42,74) 5 (55.6) 4 (44.4) 3 (33.3) 5 (55.5) 5.0 (1,9) 1 (11.1) 1 (11.1) 2 (22.2) 1 (11.1) 1 (11.1) 1 (11.1) 1 (11.1) 1 (11.1) 2.3 (1-6) PAGE 35#36Upregulation of Plasma GDF-15 Shows MDM2 Target Engagement by KT-253 at Dose Levels 1 and 2 GDF-15 is Downstream Biomarker of p53 Upregulation Following MDM2 Degradation P53 Stabilization KYMERA p53 Blood MDM2 KT-253 p53 11 MDM2 Degradation ©2023 KYMERA THERAPEUTICS, INC. Upregulation of p53 Targets Genes GDF-15- ELISA Cycle 1 Plasma Exposure and Fold-Change in GDF-15 Levels (Mean ± SEM) Dose Level DL1: 0.05 mg/kg (n = 3) DL2: 0.10 mg/kg (n = 4) Plasma GDF-15 levels (Fold Change Over Pre-dose Baseline) 25 20 15 *Max fold increase over pre-dose baseline up to D4 post-infusion; **n=3 10- AUC (ng.h/mL) 5 353 ± 236 D1 609 ± 67.3 Cmax (ng/ml) 180 ± 116 Kinetics of Plasma GDF-15 Upregulation in Subject on DL1 Cycle 1 387 ± 24.0 Max Fold Increase in Plasma GDF-15* Pre-dose baseline 10-fold 4.7 30-fold ± 19** D4 D2 D1 Time Points: Oh, 2h, 3h, 7h from Start of Infusion D8 PAGE 36#370 KT-253: Initial Clinical Activity Demonstrated in Phase 1a 23 21 42 Lesion 1 Pre-Treatment Lesion 2 Pre-Treatment 63 KYMERA ©2023 KYMERA THERAPEUTICS, INC. Days on Study - Dose Level 1 (0.05 mg/kg) 84 107 * 105 Post-Cycle 2 Post-Cycle 2 133 126 Merkel Cell Carcinoma Fibromyxoid Sarcoma Uveal Melanoma 147 Ongoing Discontinued (Progressive Disease) Partial Response Stable Disease *Patient discontinued from study 64-year-old male, diagnosed with Merkel cell carcinoma (rare and aggressive skin cancer) in 2019 Received 6 prior regimens including treatment with pembrolizumab, atezolizumab, nivolumab and ipilimumab Confirmed partial response after 4 cycles of KT-253, including resolution of skin metastasis; treatment continuing PAGE 37#38As of October 20, 2023 No dose-limiting toxicities across dose levels 1-3 Adverse events related to KT-253 and observed in at least 2 patients Nausea (n=3): Grade 1 (n=2) and Grade 2 (n=1) Diarrhea (n=2): All Grade 1 ● ● ● ● ● ● Serious adverse events (SAEs) deemed related to KT-253: Hypotension (n=1): Grade 3, occurred during cycle 4 Due to decreased oral intake; resolved with treatment including IV fluids Patient remains on study without dose reduction or recurrence of hypotension No thrombocytopenia or neutropenia even after 6 cycles of KT-253 ● KT-253 Phase 1a: Safety Update ● ● KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 38#39● ● ● ● ● KT-253: Emerging Clinical Data Support Therapeutic Hypothesis for MDM2 Degrader KT-253, unlike SMIs, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53 KT-253 inhibits tumor cell growth with picomolar activity and is more than 200-fold more potent than clinically active MDM2 SMIs, enabling intermittent dosing to improve therapeutic index Interim Phase 1a data from Arm A show evidence of target engagement and p53 pathway activation and initial signs of antitumor activity without DLTS including typical hematological toxicity Arm B (high grade myeloid malignancies including AML) enrollment initiated Additional clinical and preclinical data supporting biomarker-based patient selection strategy to be disclosed in 2024 KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-class Opportunity to Address p53 WT Tumors Across a Variety of Tumor Types First degrader against a clinically proven but inadequately drugged target, MDM2 Profound single agent activity in preclinical liquid and solid tumor models and initial evidence of antitumor activity in patients in Phase 1a Clinical development strategy includes accelerated registration path in p53 WT tumors with high sensitivity to degrader mechanism such as AML, lymphomas and solid tumors PAGE 39#40Immunology Oncology KYMERA Upcoming Milestones and Events KT-474/SAR444656 Pipeline Update KT-333 KT-253 ©2023 KYMERA THERAPEUTICS, INC. Dose first patient in Phase 2 AD trial in 4Q 2023 Estimated enrollment completion in Phase 2 HS & AD trials in 4Q 2024 Topline data expected for both studies in 1H 2025 Virtual Immunology R&D Day: January 4, 2024 Poster presentation at ASH 2023 on clinical activity: December 10, 2023 Complete Phase 1a trial in 1H 2024 Phase 1 data at medical meeting in 2024 Patient stratification and development strategy at medical meeting in 2024 Phase 1 data at medical meeting in 2024 PAGE 40#41KYMERA NASDAQ: KYMR www.kymeratx.com @KymeraTX For additional information contact: [email protected] [email protected] [email protected]